About
Overview
Leadership
Pipeline
Overview
ONCT-808
ONCT-534
Zilovertamab
Science
Overview
Publications
Investors
Overview
News Releases
Events & Presentations
Financial Reports
Stock Information
Analyst Coverage
Corporate Governance
Patients
Careers
Current Opportunities
Vision, Mission and Impact
Contact
Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study (Lee et al., ASH 2020 Virtual Annual Meeting)
Please ensure Javascript is enabled for purposes of
website accessibility
About
Overview
Leadership
Pipeline
Overview
ONCT-808
ONCT-534
Zilovertamab
Science
Overview
Publications
Investors
Overview
News Releases
Events & Presentations
Financial Reports
Stock Information
Analyst Coverage
Corporate Governance
Patients
Careers
Current Opportunities
Vision, Mission and Impact
Contact